The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_000152.5(GAA):c.716del (p.Leu239fs)

CA658795234

556853 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: e32471b6-613c-46e4-a4cd-33dfe10d4b9a
Approved on: 2020-09-20
Published on: 2020-11-12

HGVS expressions

NM_000152.5:c.716del
NM_000152.5(GAA):c.716del (p.Leu239fs)
NC_000017.11:g.80107580del
CM000679.2:g.80107580del
NC_000017.10:g.78081379del
CM000679.1:g.78081379del
NC_000017.9:g.75695974del
NG_009822.1:g.11025del
NM_000152.3:c.716del
NM_001079803.1:c.716del
NM_001079804.1:c.716del
NM_000152.4:c.716del
NM_001079803.2:c.716del
NM_001079804.2:c.716del
NM_001079803.3:c.716del
NM_001079804.3:c.716del
ENST00000302262.7:c.716del
ENST00000390015.7:c.716del
ENST00000570803.5:c.716del
More

Pathogenic

Met criteria codes 3
PVS1 PP4 PM2
Not Met criteria codes 1
PM3

Evidence Links 2

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
This variant, c.716delT (p.Leu239ArgfsTer29), is a frameshift variant that is predicted to result in a premature termination codon, nonsense mediated decay, and lack of gene product, meeting PVS1. One patient with this variant meets the ClinGen LSD VCEP’s specifications for PP4. This patient is compound heterozygous for the variant and c.1447G>A (p.Gly483Arg) (PMID 31606152, personal communication). This in trans data will be used in the assessment of p.Gly483Arg and is not included here in order to avoid circular logic. Another patient who is compound heterozygous for the variant has been reported (PMID 14695532). However, residual GAA activity was not provided and this data was not included. Therefore, PM3 is not currently met. This variant is not in gnomAD v2.1.1, meeting PM2. There is a ClinVar entry for this variant (Variation ID: 556853, 2 star review status) with one submitter classifying the variant as pathogenic and two as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PP4.
Met criteria codes
PVS1
This is a frameshift variant which is predicted to result in a premature termination codon, nonsense mediated decay, and lack of gene product. Therefore, PVS1 can be applied.
PP4
One patient with this variant has Pompe disease and deficient activity in fibroblasts (~0.5%) and dried blood spot, meeting PP4 (PMID 31606152 - personal communication).

PM2
This variant is not in gnomAD v2.1.1.
Not Met criteria codes
PM3
One patient with this variant meets PP4. This patient is compound heterozygous for the variant and c.1447G>A (p.Gly483Arg) (PMID 31606152, personal communication). This in trans data will be used in the assessment of p.Gly483Arg and is not included here in order to avoid circular logic. Therefore, PM3 is not currently met, but could be met in the future, with additional data.

Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.